Yost, Kathryn E. https://orcid.org/0000-0001-6807-950X
Zhao, Yanding
Hung, King L. https://orcid.org/0000-0002-3662-4662
Zhu, Kaiyuan https://orcid.org/0000-0001-9976-6505
Xu, Duo
Corces, M. Ryan https://orcid.org/0000-0001-7465-7652
Shams, Shadi
Louie, Bryan H.
Sarmashghi, Shahab https://orcid.org/0000-0003-0564-1643
Sundaram, Laksshman https://orcid.org/0000-0002-8953-3940
Luebeck, Jens
Clarke, Stanley https://orcid.org/0000-0002-0285-0549
Doane, Ashley S. https://orcid.org/0000-0002-1489-1786
Granja, Jeffrey M.
Choudhry, Hani https://orcid.org/0000-0003-0401-6619
Imieliński, Marcin https://orcid.org/0000-0002-2211-4741
Cherniack, Andrew D. https://orcid.org/0000-0003-0470-0111
Khurana, Ekta https://orcid.org/0000-0002-4351-7566
Bafna, Vineet https://orcid.org/0000-0002-5810-6241
Felau, Ina
Zenklusen, Jean C.
Laird, Peter W. https://orcid.org/0000-0001-9117-3641
Curtis, Christina https://orcid.org/0000-0003-0166-3802
,
Greenleaf, William J. https://orcid.org/0000-0003-1409-3095
Chang, Howard Y. https://orcid.org/0000-0002-9459-4393
Article History
Received: 29 November 2023
Accepted: 2 April 2025
First Online: 12 May 2025
Competing interests
: H.Y.C. is a cofounder of Accent Therapeutics, Boundless Bio, Cartography Biosciences and Orbital Therapeutics; was an advisor of 10x Genomics, Arsenal Biosciences, Chroma Medicine and Spring Discovery until 15 December 2024 and is an employee and stockholder of Amgen as of 16 December 2024. K.E.Y. is a consultant for Cartography Biosciences. A.D.C. receives research funding from Bayer and is a consultant for KaryoVerse. P.W.L. is an advisor for Tagomics, FOXO Biosciences and AnchorDX. W.J.G. is named as an inventor on patents describing ATAC–seq methods. 10x Genomics has licensed intellectual property on which W.J.G. is listed as an inventor. W.J.G. holds options in 10x Genomics and is a consultant for Ultima Genomics and Guardant Health. W.J.G. is a scientific cofounder of Protillion Biosciences. V.B. is a cofounder, serves on the scientific advisory board of Boundless Bio and Abterra and holds equity in both companies. The other authors declare no competing interests.